Key Proteo and Thermo-Fisher signed on MOU in August 2022

We are excited that our technology has been recognized by major instrumental company. Thermo-Fisher and Key Proteo will explore the potential implementation of Key Proteo’s technology on Thermo’s Medical Device instruments - specifically evaluating Key Proteo’s novel peptide technology for use in newborn screening applications. Dr. Hahn, CEO said in a statement that this strategic partnership will allow Key Proteo’s technology to quickly verify and validate the assay for the use of next-generation newborn screening that can detect previously undetectable diseases. Key Proteo and Thermo Fisher’s Chromatography Mass Spectrometry Division (CMD) will explore the benefits of a partnership to enable and enhance Key Proteo’s high throughput assay technology with Thermo’s mass spectrometry and liquid chromatography instruments and viability in the public market.